# Pharmacokinetic and Tolerability Study of NFC-1 in Subjects Aged 6-17 Years With ADHD

> **NCT03006367** · PHASE1 · COMPLETED · sponsor: **Aevi Genomic Medicine, LLC, a Cerecor company** · enrollment: 32 (actual)

## Conditions studied

- Attention Deficit Disorder With Hyperactivity

## Interventions

- **DRUG:** NFC-1 100 mg
- **DRUG:** NFC-1 200 mg
- **DRUG:** NFC-1 400 mg
- **DRUG:** NFC-1 800 mg

## Key facts

- **NCT ID:** NCT03006367
- **Lead sponsor:** Aevi Genomic Medicine, LLC, a Cerecor company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-07
- **Primary completion:** 2017-02-26
- **Final completion:** 2017-03-06
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2021-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03006367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03006367, "Pharmacokinetic and Tolerability Study of NFC-1 in Subjects Aged 6-17 Years With ADHD". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03006367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*